风湿病学家对生物仿制药知识的评估。

IF 2 4区医学 Q3 RHEUMATOLOGY

Advances in Rheumatology Pub Date : 2025-07-17 DOI:10.1186/s42358-025-00465-4

Thayane Furtado Rolim Lima, Lia Poti Gomes Cordeiro, Kirla Wagner Poti Gomes, Carlos Ewerton Maia Rodrigues

{"title":"风湿病学家对生物仿制药知识的评估。","authors":"Thayane Furtado Rolim Lima, Lia Poti Gomes Cordeiro, Kirla Wagner Poti Gomes, Carlos Ewerton Maia Rodrigues","doi":"10.1186/s42358-025-00465-4","DOIUrl":null,"url":null,"abstract":"Introduction: Biosimilars reduce the cost of biologic therapy without compromising safety and effectiveness. In this study we evaluated Brazilian rheumatologists' knowledge and perceptions of biosimilars.Methods: Cross-sectional and descriptive study based on a questionnaire containing 17 items on familiarity, knowledge and perceptions of biosimilars.Results: Answers were received from 135 rheumatologists, of whom 97.8% were familiar with biosimilars and 92.5% had at some time prescribed them, but only 47.7% felt comfortable prescribing them to stable patients and 62.2% strongly disagreed with automatic substitution. In addition, 51.9% preferred naive patients when starting treatment with biosimilars.Conclusion: Despite the growing acceptance of biosimilars, many physicians remain reluctant. Evidence-based continuing education is essential to clarify these issues.","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"65 1","pages":"32"},"PeriodicalIF":2.0000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of rheumatologists' knowledge of biosimilars.\",\"authors\":\"Thayane Furtado Rolim Lima, Lia Poti Gomes Cordeiro, Kirla Wagner Poti Gomes, Carlos Ewerton Maia Rodrigues\",\"doi\":\"10.1186/s42358-025-00465-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Biosimilars reduce the cost of biologic therapy without compromising safety and effectiveness. In this study we evaluated Brazilian rheumatologists' knowledge and perceptions of biosimilars.Methods: Cross-sectional and descriptive study based on a questionnaire containing 17 items on familiarity, knowledge and perceptions of biosimilars.Results: Answers were received from 135 rheumatologists, of whom 97.8% were familiar with biosimilars and 92.5% had at some time prescribed them, but only 47.7% felt comfortable prescribing them to stable patients and 62.2% strongly disagreed with automatic substitution. In addition, 51.9% preferred naive patients when starting treatment with biosimilars.Conclusion: Despite the growing acceptance of biosimilars, many physicians remain reluctant. Evidence-based continuing education is essential to clarify these issues.\",\"PeriodicalId\":48634,\"journal\":{\"name\":\"Advances in Rheumatology\",\"volume\":\"65 1\",\"pages\":\"32\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s42358-025-00465-4\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s42358-025-00465-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

生物仿制药在不影响安全性和有效性的情况下降低了生物治疗的成本。在这项研究中，我们评估了巴西风湿病学家对生物仿制药的知识和看法。方法：采用一份包含17个项目的调查问卷，对生物仿制药的熟悉度、知识和认知进行横断面和描述性研究。结果：135名风湿病学家回复了问卷，其中97.8%的人熟悉生物仿制药，92.5%的人曾经开过生物仿制药，但只有47.7%的人对病情稳定的患者开生物仿制药感到放心，62.2%的人强烈反对自动替代。此外，51.9%的人在开始使用生物仿制药治疗时更喜欢初诊患者。结论：尽管越来越多的人接受生物仿制药，许多医生仍然不愿意。以证据为基础的继续教育对于澄清这些问题至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evaluation of rheumatologists' knowledge of biosimilars.

Introduction: Biosimilars reduce the cost of biologic therapy without compromising safety and effectiveness. In this study we evaluated Brazilian rheumatologists' knowledge and perceptions of biosimilars.

Methods: Cross-sectional and descriptive study based on a questionnaire containing 17 items on familiarity, knowledge and perceptions of biosimilars.

Results: Answers were received from 135 rheumatologists, of whom 97.8% were familiar with biosimilars and 92.5% had at some time prescribed them, but only 47.7% felt comfortable prescribing them to stable patients and 62.2% strongly disagreed with automatic substitution. In addition, 51.9% preferred naive patients when starting treatment with biosimilars.

Conclusion: Despite the growing acceptance of biosimilars, many physicians remain reluctant. Evidence-based continuing education is essential to clarify these issues.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances in Rheumatology Medicine-Rheumatology

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

53 weeks

期刊介绍： Formerly named Revista Brasileira de Reumatologia, the journal is celebrating its 60th year of publication. Advances in Rheumatology is an international, open access journal publishing pre-clinical, translational and clinical studies on all aspects of paediatric and adult rheumatic diseases, including degenerative, inflammatory and autoimmune conditions. The journal is the official publication of the Brazilian Society of Rheumatology and welcomes original research (including systematic reviews and meta-analyses), literature reviews, guidelines and letters arising from published material.